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Type 1 diabetes (T1D) is a T cell mediated autoimmune disease characterized by immune
mediated destruction of the insulin-producing β cells in the islets of Langerhans. Den-
dritic cells (DC) have been implicated in the pathogenesis of T1D and are also used as
immunotherapeutic agents. Plasmacytoid (p)DC have been shown to have both protective
and pathogenic effects and a newly described merocytic DC population has been shown
to break tolerance in the mouse model of T1D, the non-obese diabetic (NOD) mouse. We
have used DC populations to prevent the onset of T1D in NOD mice and clinical trials of
DC therapy in T1D diabetes have been initiated. In this review we will critically examine
the recent published literature on the role of DC subsets in the induction and regulation of
the autoimmune response in T1D.
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INTRODUCTION
Type 1 diabetes (T1D) is an autoimmune disease characterized
by immune mediated destruction of the insulin-producing β cells
in the islets of Langerhans of the pancreas. The pathogenesis of
T1D is multifactorial with genetic, immunological, metabolic, and
environmental factors all contributing (1). It begins with a loss of
self-tolerance to islet-derived self-antigens, which usually occurs
early in life. This could occur as a result of a viral infection target-
ing the pancreas or following pancreatic remodeling. These insults
lead to the death of β cells, release of self-antigens, and induction
of inflammatory cytokines such as TNF-α and IL-1-β. Dendritic
cells (DC) present within the pancreas take up released β-cell-
derived antigens and migrate to the draining lymph nodes (LN)
and activate naïve islet-specific CD4 and CD8 T cells. Depending
on the signals delivered to the T cell by DCs the T cells will dif-
ferentiate into either inflammatory effector cells such as T helper
(Th)1 cells or anti-inflammatory Th2 or regulatory (Treg) cells.
Activated islet-specific T cells then migrate to the pancreas where
they infiltrate and collect around the islets. The early infiltrates
appear to be dominated by Th2 and Treg cells; this is termed peri-
insulitis as there is little invasion into the islet. At some point, the
infiltrate becomes invasive and begins to enter and destroy the β
cells, and the balance between the regulatory and inflammatory T
cell populations is lost. The precise factors that trigger both loss of
self-tolerance and the development of invasive insulitis are not well
understood. DCs play important roles at all stages of the autoim-
mune response in T1D due to their pivotal role in activating naïve T
cells and in maintaining self-tolerance (2). This review will explore
recent developments in our understanding of the roles DC play in
the pathogenesis, and prevention, of T1D (Figure 1) as well as the
therapeutic potential of DCs for the prevention and treatment of
T1D. Much of the work in this area has been focused on the non-
obese diabetic (NOD) model of the disease. This mouse strain
spontaneously develops diabetes and shares many of the genetic
and immunological features of the human disease (3). Where pos-
sible we will highlight similarities and differences between NOD
mouse studies and relevant studies in human T1D patients.
DENDRITIC CELL SUBSETS
Since their discovery by Ralph Steinman in the 1970s (4–6) DCs
have been the subject of intense study. DCs are antigen presenting
cells (APC) that bridge the innate and adaptive immune systems
(7). They act as sentinels of the immune system through their
location in peripheral tissues, where they form a dense network,
and their ability to respond to pathogens through expression of
pathogen recognition receptors such as Toll-like receptors (TLR).
While in peripheral tissues DCs have an immature phenotype
characterized by low levels of major histocompatibility complex
(MHC) and co-stimulatory molecules (CD80, CD86) and a high
endocytic rate; the function of tissue DCs is the detection and pro-
cessing of antigen. Upon interaction with a pathogen DCs become
activated, undergo maturation and migrate to the draining LN.
This maturation leads to an increase in the expression of MHC,
CD80, and CD86, a decrease in endocytosis and a change in the
pattern of chemokine receptor expression. Mature DCs entering
the T cell zone of the draining lymph node are primed to present
antigen to naïve T cells. Even in the absence of pathogen there is
a steady state migration of DC from the periphery to the LN and
this is necessary for the maintenance of peripheral tolerance (8).
DC PHENOTYPE
There are two main classes of DC: plasmacytoid DCs (pDCs)
and conventional or classical DCs (cDCs) (7). pDCs are primarily
located in the blood and lymphoid organs and produce high levels
of type 1 interferon (IFN) following engagement of TLRs with for-
eign nucleic acids (9). pDCs express a restricted set of TLRs, TLR7,
and TLR9, that recognize foreign RNA and DNA respectively as
well as several unique markers that distinguish them from cDCs.
These include BDCA-2 and ILT7 for human pDCs and SiglecH
and Bst2 for murine pDCs. In the mouse pDCs are commonly
identified as CD11clow B220+ SiglecH+ Bst2+. Human pDCs are
CD11c− and in addition to BDCA-2 and ILT7 also express CD123
and BDCA-4 (9). There are two main populations of cDCs in
mouse: CD11c+ CD11b− CD8α+ Clec9A+ and CD11c+ CD11b+
CD8α− Clec9A− commonly referred to as CD8 DC and CD11b
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FIGURE 1 | Summary of the roles of cDC and pDC in the prevention and induction ofT1D.
cDC respectively. Both CD8 and CD11b cDC arise from a com-
mon precursor characterized by expression of the C-type lectin
receptor DNGR-1, but it appears that pDC arise from a distinct
precursor as yet to be defined (10, 11). Recently the CD11b cDC
population has been further subdivided on the basis of endothelial
cell selective adhesion molecule (ESAM) expression (12). Simi-
lar populations can be identified in human such that CD11c+
Clec9A+ BDCA-3+ DCs correspond to CD8 cDC and CD11c+
CD11b+ BDCA-1+DCs are analogous to CD11b cDC. These pop-
ulations mainly reside in the secondary lymphoid organs and are
present during steady state. Similar populations exist in periph-
eral tissues but they express a slightly different set of markers (7).
CD11c+ CD11b− CD103+ DC and CD11c+ CD11b+ CD103+
DC in the periphery are equivalent to the CD8 cDC and CD11b
cDC populations respectively (13).
FUNCTIONAL DICHOTOMY IN cDC SUBSETS
The two cDC populations also have distinct functions with respect
to pathogen recognition, cytokine production, and T cell activa-
tion. CD8 and CD103 cDCs express a unique pattern of TLR and
other pathogen recognition receptors: they are the only subset to
express TLR3 and TLR11 and also uniquely express the C-type
lectin Clec9A, DEC205 (CD205), and langerin (CD207) (7, 9).
CD8 and CD103 cDC are specialized in the cross-presentation of
externally derived antigen on MHC class I for the activation of
naïve CD8 T cells. The recent advances in the molecular mecha-
nisms of cross-presentation are covered in a review included in this
Research Topic (14). In addition, CD8 cDC appear to preferentially
activate CD8 T cells due to the fact that they produce high levels
of the cytokines interleukin (IL)-12 and IL-15 that are important
for the differentiation and survival of CD8 T cells (15–17). CD8
and CD103 cDCs are the main producers of IL-12, an important
cytokine in the differentiation of inflammatory Th1 cells (15, 16,
18). There are also reports suggesting a role for CD8 and CD103
cDCs in the maintenance of peripheral self-tolerance through the
deletion of self-reactive T cells (19, 20) and the induction of Treg
cells (21). While CD11b cDC are capable of cross-presentation and
CD8 T cell activation they appear to be most effective in antigen
presentation and activation of CD4 T cells (22) In addition the
dermal and intestinal CD11b+ CD103+ DCs are strong induc-
ers of Treg due to their expression of aldehyde dehydrogenase, the
enzyme that converts Vitamin A to retinoic acid, necessary for Treg
conversion (23, 24). Several comprehensive reviews on DC subsets
and their development have recently been published and can be
consulted for further details (7, 9, 13).
DC AND THE MAINTENANCE OF SELF-TOLERANCE
T and B cell tolerance to self-antigens is acquired during devel-
opment through clonal deletion of self-reactive cells. DC play an
important role in the process of central tolerance in the thymus as
they present an array of self-antigens to developing T cells (25). If
the T cells have a high affinity for self-antigen they undergo apop-
tosis and are deleted. Those T cells with a moderate affinity for
self are induced to differentiate into forkhead transcription factor
(Foxp3)+ suppressor cells (26) known as thymus (t)Treg (27). In
contrast, peripheral (p)Treg cells arise in the periphery upon Ag
contact and several subsets of pTreg can be induced depending on
the signals they encounter (28). These include IL-10 (29), TGF-β
(30), retinoic acid or vitamin D3 (31, 32), low Ag dose (33), and
specific DC subsets (21, 34, 35). As the study of DC biology has
evolved, it has become apparent that it is possible to induce the
differentiation of Treg using DCs conditioned by immunomodu-
latory agents (36–39). For example, the presence of TGF-β during
the primary stimulation induces the production and expansion of
Foxp3+ Treg (35). In addition it has been possible to induce IL-
10-producing T cells with DC generated using a combination of
GM-CSF, TNF-α, and IL-10 (39). Studies have shown that DC pro-
ducing IDO induce the generation of Treg from naïve T cells (40).
Other reports have suggested that immature DC induce the devel-
opment of functional suppressor cells (36) and that immature DC
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might, therefore, be therapeutically useful in autoimmunity (37,
38). Recent studies using both nominal and self-Ags have demon-
strated that targeting Ags to CD8 cDC in the LN or spleen in
the absence of an inflammatory stimulus results in the genera-
tion of Treg (41, 42). Similar results have been obtained when Ags
were targeted to CD8− DCIR2+ DC (21). The CD11b cDC sub-
set has been shown to induce Treg proliferation and expansion
in the presence of GM-CSF (43). A recent paper has described a
feedback loop in which the number of Tregs in the periphery can
be manipulated by altering the relative number of DCs suggesting
that DCs play an important role in regulating pTreg numbers (44).
We have recently suggested that DC in the periphery may function
to maintain tolerance by presenting endogenous self-antigens to
naïve T cells thereby inducing pTreg (45).
THE ROLE OF DENDRITIC CELLS IN THE
PATHOGENESIS/PREVENTION OF T1D
DC DEVELOPMENT IS DEFECTIVE IN T1D
Early studies of NOD mouse revealed abnormalities in the devel-
opment of myeloid cells demonstrating a reduced proliferative
capacity of the bone marrow in response to GM-CSF and M-CSF
(46). Several groups, including our own, have identified defects in
the development of specific DC subsets in the spleen and other
lymphoid organs (47–49). These defects result in a decrease in the
numbers of the CD8 cDC population (50, 51), a population which
has been shown to have regulatory function (52–54), with a con-
comitant increase in the CD11b cDC population. Recent studies
have also shown that treatment of NOD with Flt 3 ligand (FL)
protects mice from diabetes development and this is correlated
with an enhancement in the number of CD8 cDC (55, 56). Our
own studies demonstrated that treatment of NOD mice with FL
increased the number of CD8 cDC and that transfer of these cells
to prediabetic NOD mice could have a partial effect in preventing
diabetes (50). However a recent study suggested that the timing
of FL treatment was critical since disease would be exacerbated if
autoimmune CD8 T cells were already present (57).
Several studies have examined the function of bone marrow-
derived and isolated DC populations with respect to cytokine
production and T cell differentiation and the results have not
been consistent. It has been reported by some investigators that
NOD DC produce higher levels of the Th1-driving cytokine IL-12
(58–60) while others failed to find such an association (49, 50,
56). Macrophages also appear to be an important source of IL-
12 in NOD mice (51, 61). Adenosine plays an important role in
modulating the immune response to tissue inflammation (62, 63)
and a recent study found that NOD DC express higher levels of
adenosine deaminase (ADA), the enzyme responsible for catabolic
degradation of adenosine, and that transfer of ADA deficient DC to
NOD mice protected them from diabetes (64). These studies sug-
gest that NOD mice have imbalances in DC subsets and alterations
in DC function that may contribute to pathogenesis of T1D.
DC AND THE MAINTENANCE OF TOLERANCE IN T1D
Dendritic cells are important in both central and peripheral toler-
ance through the deletion of self-reactive cells and the induction
of Treg. NOD mice have defects in central and peripheral toler-
ance mechanisms (65, 66). Recent studies have shown that the
number and/or function of Treg cells decrease as NOD mice age
and this is associated with onset of diabetes (67). The development
and maintenance of Treg in NOD mice is highly dependent on
the presence of co-stimulatory molecules CD80 and CD86 (68).
In addition it was recently shown that interaction between the
inhibitory molecules PD-1 on T cells and PDL-1 on DC is neces-
sary for the maintenance of tolerance in NOD mice (69). Blockade
of this interaction resulted in increased DC/T cell interaction time
in the islets and T cell activation leading to the generation of
autoreactive effector cells (69). Another study came to the same
conclusion by using different antigen constructs to increase the
time of antigen presentation (70). IL-2 and signaling via IL-2R are
also critical for Treg development and maintenance (71). Recent
studies have identified defects in IL-2R signaling in T1D patients
(72) and the diabetes susceptibility locus, Idd3, which contains IL-
2 was recently shown to control Treg function through an effect on
APC (73–75). Several early reports demonstrated that the inflam-
matory cytokine TNF-α plays an important role in the initiation
of T1D (76) and more recently this has been attributed to effects of
TNF-α on DC subsets (77). In this study administration of TNF-
α to NOD mice was shown to decrease the number of CD8 DC,
increase the CD11b DC population,and the DC had a more mature
phenotype and activated islet-specific T cells (77) A recent study
describing the depletion of Treg in NOD mice showed that the
increase in diabetes in these animals was associated with aggres-
sive infiltration of pancreatic islets by DC rather than CD4 T cells
(78). These results suggest that tTreg in this context may prevent
autoimmunity by controlling the migration of cDC into the islet.
DC CONTRIBUTE TO THE DEVELOPMENT OF T1D
Analysis of the phenotype and function of BM-derived DC in
NOD mice have suggested that these cells produce higher levels
of IL-12p70, and that this related to increased expression of NFκB
(58). Our own studies suggest that BM-derived DC from NOD
can produce higher or lower levels of IL-12p70 depending on the
culture conditions and activation stimuli used (49, 79, 80). Recent
studies using DTR transgenic mice that allow the targeted deple-
tion of macrophages or DC have demonstrated that the CD11b
cDC population is responsible for presenting antigen to autore-
active T cells (81). Ablation of these cells protected NOD mice
from diabetes development. The interaction of iNKT cells with
cDC was shown to lead to either protection via induction of Treg
or exacerbation of disease if the interaction occurred at the same
time as TLR4 ligation (82).
The role of pDC in diabetes pathogenesis is somewhat more
controversial and there are conflicting reports in the literature.
Depletion of pDC using the CD11c-DTR system caused accel-
erated disease (81), suggesting a protective role for pDC. The
protection induced by pDC was correlated with increased local
production of IDO and increased numbers of NKT cells in the
pancreas. In a model of virus infection it was shown that activa-
tion of iNKT cells stimulated TGF-β production from pDC, which
led to the induction of Treg and protection from diabetes (83). In
contrast, another study found that IFN-α could be detected in the
pancreas of NOD mice at early ages and that blocking the ability
of mice to respond to IFN-α prevented diabetes (84). Furthermore
these investigators showed that depletion of pDC using a depleting
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antibody reduced the incidence of diabetes (85). Another study
revealed a crosstalk between B-1a B cells, neutrophils and pDC
that contributed to the induction of diabetes via type 1 IFN pro-
duction (86). This study suggests that DNA from dying β cells
together with antibodies from B-1a B cells form complexes that
are potentiated by neutrophils and lead to the induction of type 1
IFN by pDC (86). The authors show that this is seen only in NOD
mice and speculate that this is related to the defects in the ability
of NOD macrophages to clear debris (87). Several studies have
examined the role of pDC, type 1 IFN and viral infection in the
induction of T1D; reviewed in Swiecki et al. (88). The situation
is complex with some studies showing exacerbation of diabetes
(89, 90) with viral infection and others showing protection (91,
92). It has been suggested that whether viral infection leads to
diabetes induction is related to the tropism of the virus and the
local environment in which type 1 IFN is produced (88). Thus a
virus infecting the pancreas may induce local type 1 IFN, which
protects islets from infection and damage, whereas in other situa-
tions the type 1 IFN, produced by pDC following viral infection,
could result in activation of autoreactive T cells and diabetes exac-
erbation (88). It has been reported that pDC also accumulate in
the islets of NOD mice (93) at a later time point, around 10 weeks
of age. The infiltrating pDC were shown to express IDO, which is
characteristic of a more tolerogenic phenotype of DC (94) leading
to the speculation that these cells may be attempting to control
ongoing T cell activation. Studies in the next few years will hope-
fully clarify these contrasting results on the role that pDC play in
diabetes pathogenesis.
A novel population of cDC, termed merocytic (mc)DC, have
recently been identified and shown to be responsible for cross-
presentation of islet antigens to CD8 T cells and direct presentation
to CD4 T cells (95, 96). The mcDC express CD11c but are neg-
ative for both CD11b and CD8, they accumulate in the spleen as
NOD mice age and were shown to secrete large amounts of type
1 IFN (95, 96). In addition transfer of mcDC pulsed with irra-
diated islets to non-diabetic NOD mice accelerated the onset of
diabetes (95, 96). The number of mcDC was recently mapped to
the Idd13 congenic interval suggesting that the relative number
of these cells is genetically determined (97). Further studies are
required to determine the significance of this DC population, and
whether a counterpart of these cells exists in human.
Dendritic cells are constitutively present within islets of nor-
mal mice and have been shown to express peptide-MHC (pMHC)
complexes containing peptides derived from islet antigens (98).
Two major DC subsets can be found within islets; the CD11b
cDC and CD103 cDC (99, 100). CD103 DC depend on FL for
their homeostasis whereas islet CD11b DC appear to arise from
monocytes and are unaffected by the absence of FL (101). The
number of DCs in the islets remains relatively stable but these
numbers increase following T cell infiltration and inflammation
(98, 99, 102). In addition the phenotype of the DC becomes more
inflammatory with increases in the expression of co-stimulatory
molecules and MHC (2). The evidence suggests that the initiation
of the autoimmune response occurs within the draining pancre-
atic lymph node (PLN) since removal of the PLN prevents diabetes
(103) and several studies have shown that the initial proliferation
of islet-specific CD4 and CD8 T cells takes place in the PLN (104,
105). Islet CD103 DC migrate to the PLN where they present islet
antigens to specific CD4 and CD8 T cells (2, 101), and when T cells
infiltrate the islet they localize to DC-rich areas (2). The movement
of DC and T cells within the islet can now be visualized using a
novel two-photon imaging technique (106). In addition pancre-
atic CD103 DC from NOD mice have been shown to express less
IL-10 than similar populations from non-diabetic strains suggest-
ing that these have lost their ability to induce tolerance (107). Islet
CD11b DC are relatively poor at presenting antigen under steady
state conditions but they accumulate as inflammation increases
and become more mature. Since CD11b DC do not appear to
migrate to PLN their role appears to be in the modulating the
local tissue response (101).
DC IN HUMAN T1D
Several studies have examined the blood of newly diagnosed T1D
patients for the presence of DC subsets. pDCs have been shown
to be increased (108) or decreased (109) at the time of diagnosis.
A recent detailed longitudinal analysis of immune parameters in
newly diagnosed T1D children has revealed that reduced numbers
of cDC1s and NKT cells at the time of diagnosis are correlated
with reduced residual β cell function 1 year later (110). Another
study found decreased numbers of cDCs and pDCs in newly diag-
nosed pediatric T1D patients and also observed a decrease in
the expression of CCR2 on these cells (111). Other studies have
found correlations with vitamin D levels and immune cells in T1D
patients (112). A study of pancreatic biopsies on a small number
of new onset T1D patients revealed the presence of infiltrating
macrophages and DC that produce TNF-α (113). A recent descrip-
tion of three cases of fulminant T1D secondary to enterovirus
infection revealed marked islet infiltration of activated DC and
macrophages and the presence of inflammatory cytokines (114).
Thus it is likely that DCs will be shown to contribute to the onset
of human T1D.
DENDRITIC CELLS AS THERAPY FOR T1D
The fact that DCs play an important role in the induction and
maintenance of self-tolerance has made them attractive targets
for therapeutic interventions. Three main strategies have been
employed and these include the adoptive transfer of specific DC
subsets, the in vitro expansion of Tregs with specific DCs and the
in vivo targeting of DC subsets (115). As discussed above the com-
plexity of DC subsets and the plasticity of their function have made
this a challenging objective, since there is a fine balance between
the immunostimulatory and immunoregulatory functions of DC
(45, 116, 117). DCs with a so called semi-mature phenotype, which
consists of increased MHC and co-stimulatory molecule expres-
sion but low inflammatory cytokine production are thought to be
most effective in inducing tolerance in the context of autoimmu-
nity (118, 119). This maturation state can be induced by exposing
DC to the cytokine TNF-α and DCs treated in this way have been
shown to prevent experimental allergic encephalomyelitis (EAE)
(118). In general the function of these DCs is to induce the expan-
sion of Treg or other regulatory mechanisms such as Th2 cells.
The attraction for using DCs as therapeutic agents is that since
they present specific antigen to T cells it is possible to envision the
generation of antigen-specific tolerance (120).
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ADOPTIVE TRANSFER OF THERAPEUTIC DC
Dendritic cells were first used as therapeutic agents to prevent dia-
betes in NOD mice over 20 years ago by Clare-Salzler et al. (121).
In this study DCs isolated from the PLN of NOD mice and trans-
ferred to prediabetic NOD mice were able to prevent disease onset
whereas DCs from other LN or spleen were not effective. Later
studies by the same group have suggested that DC in the PLN
are more mature and that this is important for their therapeutic
effect (122). We have previously shown that the injection of semi-
mature bone marrow-derived DC prior to the onset of destructive
insulitis prevents the subsequent development of diabetes (123,
124). The therapeutic DC populations expressed high levels of co-
stimulatory molecules (CD80, CD86, and CD40) and produced
low levels of IL-12p70 following CD40 ligation (49). Further inves-
tigation revealed that the therapeutic DC population changed the
cytokine milieu in treated NOD mice. Whereas NOD mice gen-
erally exhibit a strong bias toward type 1 cytokine production,
injection of DC induced the production of type 2 cytokines (125).
In addition we (124) and others (126, 127) showed that injection
of DC transduced with the IL-4 gene could effectively prevent
diabetes in NOD mice when given at later time points, past the
onset of invasive insulitis. We also confirmed, using in vitro stud-
ies, that therapeutic DC could drive the differentiation of Th2 cells
(79), whereas non-therapeutic DC did not. The therapeutic DCs
were not treated with any tolerogenic agents and did not require
the addition of islet-derived peptides but the cultures were per-
formed in FBS, which was subsequently shown to induce a Th2
environment that may have been non-specifically contributing to
the therapeutic effect (128). In more recent experiments we have
shown that the therapeutic DC population induces the expansion
of Treg in the presence of low dose antigen (129) and DCs cultured
in the absence of FBS are equally able to induce Treg expansion
(unpublished observations). In addition it has been shown that
DC grown in autologous serum were able to prevent diabetes but
only when pulsed with insulin-derived peptides (130).
In order to ensure that DCs maintain a tolerogenic pheno-
type and drive tolerance rather than immunity several approaches
aimed at conditioning the DC have been explored. These have
included treating DC with cytokines such as IL-10 (130, 131), IL-
10/TGF-β (132), and TSLP (IL-25) (133), pharmacological agents
such as dexamethasone and vitamin D3 (134), carbon monox-
ide (CO) (135), anti-CTLA-4 antibody (136), secretory IgA (137)
among others. In general, the treatment of DCs with these agents
induces a semi-mature phenotype in the DC characterized by
reduced expression of co-stimulatory molecules, reduced inflam-
matory cytokine production and resistance to further maturation
stimuli. The infusion of these modified DC into NOD mice results
in the deletion of autoreactive CD4 T cells and the generation
of islet-specific Treg (130, 131, 133, 136, 137). One exception to
this was the treatment of NOD mice with CO-treated DC, which
reduced β1-integrin expression by CD8 T cells and thus inhibited
their migration into the islet (135). Another approach has been the
use of anti-sense oligonucleotides to down-regulate the expression
of the co-stimulatory molecules, CD40, CD80, and CD86 on DC
(138). This approach prevented diabetes in NOD mice through the
induction of Treg and a phase 1 clinical trial using this approach
was initiated (139).
DC USED TO EXPAND REGULATORY T CELLS IN VITRO
Dendritic cells have also been used in vitro in order to expand Treg
cells, and these Treg can be adoptively transferred into individu-
als with autoimmunity with the hope of curbing or arresting the
inflammatory response. An early study expanded Treg, isolated
from an islet-specific TCR transgenic NOD mice (BDC2.5), with
peptide pulsed DC and IL-2 and showed that these cells could
prevent diabetes in prediabetic NOD mice (34). Further stud-
ies from this group indicated that DC expressing higher levels
of the co-stimulatory molecule, CD86 were the most efficient at
inducing Treg expansion (140). The CD11b cDC subset has been
shown to induce Treg proliferation and expansion in the presence
of GM-CSF (43). A recent study examining the mechanism by
which GM-CSF treatment prevents diabetes has further suggested
that the expression of OX40L and the Notch3 ligand Jagged1 on
DC was necessary for Treg expansion in vitro, although this study
did not determine whether these polyclonal expanded Treg were
effective in preventing diabetes (141). Some of the approaches to
generate tolerogenic DC are being developed for clinical trial in the
context of transplantation (142) but these are not yet being fully
developed for use in autoimmune disease. A recent study com-
pared the ability of several DC conditioning regimens to induce
suppressive Treg in the human system (143). This study found that
DC pretreated with IL-10 induced the most suppressive Treg, while
TGF-β, rapamycin, and dexamethasone were less effective (143).
IN VIVO TARGETING OF DC
In general these types of therapies have involved the use of reagents
that deliberately target specific DC subsets but these can also
include approaches that, while not directly targeting DC, act by
changing the local DC environment. Recent studies using both
nominal and self-antigens have demonstrated that targeting anti-
gens to CD8 cDC in the LN or spleen using anti-CD205 antibodies
coupled to specific antigens in the absence of an inflammatory
stimulus results in the generation of Treg (41, 42). Similar results
have been obtained when antigens were targeted to CD11b cDC
(21). A recent study used anti-CD205 antibodies coupled to the
peptide mimetope for the CD4 BDC2.5 T cell to target DC in
NOD mice (144). This resulted in the generation of long-lived and
stable BDC2.5 Treg but this had no impact on the development
of diabetes. However when the anti-CD205 was coupled to the
proinsulin protein diabetes was prevented (144). Similar studies
using an anti-CD205 coupled to HA and given to INS-HA/TCR-
HA mice also demonstrated efficacy in the prevention of diabetes
(145). In this mouse model the foreign antigen HA is expressed
in the pancreas under the control of the rat insulin promoter and
the T cells are all transgenic for an HA-specific TCR (145). These
results suggest that the choice of antigen for targeting will be crit-
ical if this approach is to move forward. A similar approach has
been used to induce tolerance in islet-specific CD8 T cells. These
studies reported initial activation of adoptively transferred islet-
specific CD8 cells followed by deletion of these cells, but the impact
of these on diabetes development was not reported (146).
It has been known for some time that varying the dose of the
stimulating antigen has a profound effect on T cell differentiation
(147–149). Interest in this area has been renewed by the obser-
vation that the induction of Treg is optimal in situations of low
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TCR signal strength (33, 129, 150). The induction of Treg by low
dose antigen occurs optimally when DC are presenting the antigen
(129), and while the addition of TGF-β is not necessary a recent
study showed that TGF-β production by T cells is required (151).
Interestingly the most effective induction of Treg in vivo occurs
when low doses of a high affinity peptide are used, rather than
higher doses of low affinity peptides (152). Furthermore it was
recently shown that the affinity of the peptide affects the duration
of DC/T cell contacts in vivo providing an explanation for why low
dose of more potent pMHC complexes are most effective at dri-
ving Treg expansion in vivo (153). Several approaches have been
attempted to deliver low dose antigen in vivo including the con-
tinuous delivery of low dose antigen via osmotic pump (154) and
the direct targeting of DC subsets as discussed above (21, 41, 42).
In the context of T1D a recent study demonstrated that low doses
of a high affinity insulin peptide mimetope was more effective
at preventing diabetes than the native peptide (155). These results
suggest that long-lasting peripheral tolerance could be achieved by
delivering the appropriate dose of antigen to steady state DC in the
periphery. The challenge will be translating this to the human situ-
ation although a recent paper showed that human insulin-specific
Treg could be induced by low dose stimulation (156).
Another way to target DC in vivo is to use microparticles
(157). A recent study used microspheres loaded with anti-sense
oligonucleotides specific for CD40, CD80, and CD86 and showed
prevention of diabetes along with an increase in Treg in treated
NOD mice (158). These investigators further showed that repeated
treatment with these microspheres could reverse diabetes in newly
diagnosed NOD mice. The microspheres were taken up by resident
DC in the spleen and these DC showed reduced expression of the
co-stimulatory molecules (158).
In a study of combined therapy with oral anti-CD3 and intra-
venous anti-CD20 antibodies the prevention of diabetes seen in
these animals was correlated with an increase in Treg and IL-10-
producing T cells. Furthermore a population of IL-27 producing
DCs was found to be responsible for the induction of IL-10-
producing T cells in this system (159). As discussed above FL
treatment of NOD mice in some circumstances prevents T1D (55,
56) but the timing of FL administration has to be before the onset
of autoimmunity otherwise disease is exacerbated (57). Treatment
of NOD mice with soluble CTLA-4 has been shown to restore the
tolerance inducing properties of DC through the IFN-γ dependent
activation of IDO. In this model CTLA-A binds to B7 molecules
on DC and this stimulates the release of IFN-γ, which activates the
immunosuppressive mechanism of tryptophan catabolism (160).
A novel approach has been to induce accumulation of thymic DC
populations which results in an increase in suppressive Tregs. A
recent study identified the delta-like ligand 4 (Dll4)-Notch signal-
ing pathway as important in controlling the number of thymic
DCs (161). These investigators found that blockade of the Dll4-
Notch pathway resulted in an increase in thymic DC numbers and
thymic Treg. Treatment of NOD mice with these blockers not only
prevented the establishment of disease in prediabetic animals but
also was able to reverse disease in newly diagnosed diabetic animals
(161). This protection was dependent on the presence of Treg since
treatment of non-diabetic animals with a Treg-depleting antibody
reversed the protection (161). Several studies have reported the
use of α-GalCer, an agonist for iNKT cells, as a means to prevent
disease in NOD mice (162–164). Recent studies have suggested
that α-GalCer treatment induces tolerogenic DC populations that
induce non-inflammatory islet-specific T cells (165), and novel
derivatives of α-GalCer have been developed that have the same
effect without some of the profound suppressive effects on iNKT
function (166).
CLINICAL TRIALS IN T1D INVOLVING DC
As discussed above a phase I clinical trial utilizing autologous
monocyte-derived DC treated with anti-sense oligonucleotides to
down-modulate co-stimulatory molecules has been conducted. In
this trial of 10 patients with established T1D, 7 were given the
immunosuppressive DC and 3 were given unmanipulated DC.
In this trial no adverse events were observed and there were few
changes noted in terms of insulin requirements, immune cell
phenotype, and cytokine production (139). Interestingly, further
analysis of this clinical trial revealed an increase in certain B cell
populations and subsequent in vitro studies revealed that human
DC treated with these anti-sense oligonucleotides could induce the
proliferation of immunosuppressive B cells (167). A second trial
using this same approach is now ongoing but results are not yet
available. The field of DC-based vaccines is much more advanced
in the setting of cancer and many clinical trials have been con-
ducted; reviewed in the current Research Topic (Butterfileld, under
review). Many features of cancer DC vaccines have been studied
and it has become apparent that characteristics such as the form
of the antigen used to pulse the DC, the conditioning regimen of
the DC, and the route of administration all play critical roles in
determining the outcome of the DC-based immunization. These
features will need to be taken into consideration as more DC-based
therapies are proposed for the treatment of T1D. There have been
numerous clinical trials in T1D with the aim of inducing antigen-
specific tolerance (168). These trials utilize islet-derived antigens,
such as insulin GAD65 or hsp 70, and various routes of admin-
istration have been tested including oral, nasal, and intradermal.
So far these trials have failed to have a significant impact on dis-
ease although in some cases evidence for immune tolerance was
observed (168). It is to be expected that the success of such trials
will depend on the APC, most likely a DC, targeted by these anti-
gen formulations. At the present time not much attention is being
paid to the nature of the DC presenting the antigen in these trials
but, in view of our increasing understanding of the complexity of
DC phenotype and function this is likely to change.
FUTURE PERSPECTIVES
As discussed at the beginning of this review many of the stud-
ies that examine the therapeutic potential of DC in the treat-
ment/prevention of T1D have been performed in the NOD mouse.
This has been a very useful model for identifying susceptibility
genes and understanding the progression to disease but thera-
peutic approaches that have successful in this mouse model have
not translated well to the clinic (169). DCs play a pivotal role in
setting the tone of the immune response. On the one hand they
contribute to the development and maintenance of self-tolerance
and on the other they contribute to the breaking of that tolerance
and the initiation of disease. A deeper understanding of how DC
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can influence the development of autoimmune diabetes will aid
in the development of novel therapeutic strategies. A great deal of
progress has been achieved in the last several years and we have a
better understanding of how DC can both maintain and break self-
tolerance. The challenge in the future will be to use this knowledge
to achieve the ultimate goal of inducing antigen-specific tolerance
to prevent autoimmunity without causing widespread immune
suppression.
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